Top Gainers: CRPB Jumps 229.2% due to Release of Data for ADC Tumor Candidate

CRPB

Last week, Corbus Pharmaceuticals announced that data from the first-in-human clinical study of CRB-701 (SYS6002) were presented at the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium.

A mixed tumor population (n=7) receiving doses of 2.7 mg/kg or 3.6 mg/kg demonstrated an ORR of 43% (3 partial responses -2 unconfirmed and one non-responding participant with no-nectin-4 expression) and a disease control rate of 71%.

The longest observed response to date is 11 cycles (~10 months) and ongoing. The update sent shares trade over 200% higher.

FGEN

SAN FRANCISCO, Jan. 25, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) announced graduation and completion of the pamrevlumab experimental arm in the Pancreatic Cancer Action Network's (PanCAN) Precision PromiseSM Phase 2/3 adaptive platform trial, which evaluates pamrevlumab in combination with the chemotherapy treatments gemcitabine and nab-paclitaxel for patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). Topline data from this registration study is anticipated in the second quarter of 2024.

PEPG

Stifel Nicolaus analyst Paul Matteis maintained a Buy rating on PepGen Inc. on January 26 and set a price target of $24.00. The company"s shares closed last Tuesday at $10.93.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for PepGen Inc. with a $23.67 average price target, a 216.0% upside from current levels. In a report released yesterday, Wedbush also maintained a Buy rating on the stock with a $21.00 price target.

Momentum Investing

On paper, momentum investing seems less like an investing strategy and more like a knee-jerk reaction to market information. The idea of selling losers and buying winners is seductive, but it flies in the face of the tried and true Wall Street adage, buy low, sell high.

Momentum investing is a trading strategy in which investors buy securities that are rising and sell them when they look to have peaked.The goal is to work with volatility by finding buying opportunities in short-term uptrends and then sell when the securities start to lose momentum.Then, the investor takes the cash and looks for the next short-term uptrend, or buying opportunity, and repeats the process.Skilled traders understand when to enter into a position, how long to hold it for, and when to exit; they can also react to short-term, news-driven spikes or selloffs.

Risks of momentum trading include moving into a position too early, closing out too late, and getting distracted and missing key trends and technical deviations.

Top Gainers of  This Week

Explore the market movers and top stock gainers in the US stock market, capturing notable surges in stock prices. Stay informed about these movers, leveraging real-time data and historical trends to make informed investment decisions.